Preferred Label : Hyperoxaluria, primary, type I;
Symbol : HP1;
CISMeF acronym : HP1;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Peroxisomal alanine:glyoxylate aminotransferase deficiency; Glycolic aciduria; Hepatic agt deficiency; Serine:pyruvate aminotransferase deficiency; Alanine-glyoxylate aminotransferase deficiency; Oxalosis I;
Description : Primary hyperoxaluria type I is an autosomal recessive disorder characterized by an
accumulation of calcium oxalate in various bodily tissues, especially the kidney,
resulting in renal failure. Affected individuals have decreased or absent AGXT activity
and a failure to transaminate glyoxylate, which causes the accumulated glyoxylate
to be oxidized to oxalate. This overproduction of oxalate results in the accumulation
of nonsoluble calcium oxalate in various body tissues, with pathologic sequelae (Takada
et al., 1990; Danpure et al., 1989; Williams et al., 2009) - Genetic Heterogeneity
Type II primary hyperoxaluria (HP2; 260000) is caused by mutation in the glyoxylate
reductase/hydroxypyruvate reductase gene (GRHPR; 604296) on chromosome 9. Type III
primary hyperoxaluria (HP3; 613616) is caused by mutation in the mitochondrial dihydrodipicolinate
synthase-like gene (DHDPSL; 613597) on chromosome 10q24.;
Inheritance : Autosomal recessive;
Molecular basis : Caused by mutation in the alanine-glyoxylate aminotransferase gene (AGXT, 604285.0001);
Laboratory abnormalities : Hyperoxaluria; Hyperoxalemia; Hyperglycolic aciduria; Diffuse deposition of calcium oxalate in various tissues; Decreased AGT activity;
Prefixed ID : #259900;
Origin ID : 259900;
UMLS CUI : C0268164;
Automatic exact mappings (from CISMeF team)
Broader ORDO disease(s)
DO Cross reference
Genes related to phenotype
HPO term(s)
ORDO concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to NTBT